Thousand Oaks, CA, United States of America

Thomas Storz



Average Co-Inventor Count = 2.4

ph-index = 1

Forward Citations = 25(Granted Patents)


Location History:

  • Thousand Oaks, CA (US) (2003 - 2012)
  • Warwick, NY (US) (2012)

Company Filing History:


Years Active: 2003-2012

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Certainly! Here is the article about inventor Thomas Storz:

Title: Exploring the Innovations of Thomas Storz in Therapeutics: A Story of Patent Success

Introduction:

Thomas Storz, a prolific inventor based in Thousand Oaks, CA, has made significant contributions to the field of therapeutics through his groundbreaking patents. With a total of 6 patents to his name, Storz stands out as a visionary in the realm of medical innovation.

Latest Patents:

Storz's latest patents revolve around the development of antagonists of the bradykinin B1 receptor. These compositions involve bradykinin B1 receptor antagonist peptides conjugated to both univalent and multivalent vehicles, offering novel therapeutic avenues for conditions such as inflammation and pain associated with the bradykinin B1 receptor.

Career Highlights:

Throughout his career, Thomas Storz has lent his expertise to renowned companies such as Amgen Inc. and Novartis AG. His tenure at these esteemed organizations has not only showcased his inventiveness but also his ability to drive impactful research in the pharmaceutical industry.

Collaborations:

Storz has had the privilege of collaborating with esteemed professionals in the field, including Gordon Ng and Yue-Sheng Li. Together, they have delved into the complexities of therapeutic development, fostering a culture of innovation and excellence.

Conclusion:

In conclusion, Thomas Storz emerges as a trailblazing inventor whose patents have the potential to revolutionize therapeutics. His relentless pursuit of scientific advancement, coupled with his collaborative spirit, underscores his significant impact in the realm of medical innovation.

(End of Article)

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…